How long should antibiotics be continued following an amputation for diabetic foot infection, particularly in cases of residual bone infection?

Introduction
Diabetic foot infections (DFIs) are among the most common and serious complications of diabetes mellitus. ^1,2 In the United States, an estimated 160,000 amputations are performed annually in people with diabetes.² Furthermore, 80% of nontraumatic lower limb amputations are a result of diabetes complications.

The management of DFIs generally requires antimicrobial therapy in conjunction with surgical intervention in cases of severely infected bone or nonviable tissue.^1,3 While antibiotic treatment durations are fairly well established for soft tissue infections and osteomyelitis managed without resection, the optimal duration of therapy following amputation is less clearly defined, especially in cases of residual bone infection, as indicated by positive bone margins following amputation.^1,3 From an antimicrobial stewardship standpoint, extended antibiotic therapy after adequate surgical source control may offer limited additional clinical benefit while increasing the risk of adverse events, antimicrobial resistance, and Clostridioides difficile infection. However, undertreatment may increase the risk for further and more extensive amputations. Consequently, determining the appropriate duration of antibiotic therapy following amputation continues to be an important and somewhat unresolved clinical challenge.

Guideline Recommendations
A 2023 joint guideline from the International Working Group on the Diabetic Foot (IWGDF) and Infectious Diseases Society of America (IDSA), focused on the diagnosis and treatment of DFI, recommends short postoperative antibiotic courses when adequate surgical source control has been achieved.³ More specifically, for patients undergoing minor amputation for DFI-related osteomyelitis with complete resection of infected bone and negative bone margins, postoperative antibiotics are generally recommended for 2 to 5 days. When bone margins are positive for residual osteomyelitis after minor amputation, up to 3 weeks of antibiotic therapy is recommended. For comparison, a total of 6 weeks of antibiotics is recommended for the treatment of DFI-related osteomyelitis that is treated without bone resection or amputation.

The recommendations regarding the duration of antibiotics following amputation are graded as conditional and based on low-certainty evidence, largely derived from a randomized, noninferiority pilot trial comparing 3 vs 6 weeks of antibiotic therapy following debridement or partial amputation for DFI-associated osteomyelitis with residual bone infection.^3,4 The trial reported comparable rates of clinical remission and adverse events between treatment durations. Overall, the guideline panel acknowledges that the evidence base is limited and with a high risk of bias.³

A 2025 guideline from the WikiGuidelines Group on the management of osteomyelitis provides recommendations largely consistent with those of IWGDF/IDSA, while adding several nuances.⁵ The group makes a clear recommendation that no more than 6 weeks of antibiotic therapy be administered for osteomyelitis, assuming adequate source control. In select cases with appropriate bone debridement, some clinicians may consider a shorter 3- to 4-week course, although they note that the current evidence is insufficient to definitively recommend 4 versus 6 weeks. Additionally, after complete resection of infected bone with clear margins, the guideline notes that withholding antibiotics entirely may be reasonable if the treating clinician is confident that all infected bone has been removed. If antibiotics are given in this setting, durations beyond 10 days have not shown benefit, and the Group does not recommend exceeding 5 days of therapy based on expert consensus. This guideline incorporates several newer studies evaluating antibiotic duration after DFI-related amputation in the setting of residual bone infection, and these will be discussed in greater detail below.

Clinical Evidence
A literature search completed in PubMed in February 2026 identified 2 comparative studies published in 2022 or later that evaluated optimal antibiotic duration after DFI-related amputation with culture-confirmed residual bone infection.^6,7 Table 1 provides a summary of characteristics and results from these studies. Both studies were single-center, international, retrospective cohorts, including mostly older adults (median age range, 67 to 71 years) and men (82% to 83%) who underwent toe or trans-metatarsal amputation for DFI-related forefoot osteomyelitis. In a 2022 study, an antibiotic duration $\lt$4 weeks versus ≥4 weeks was compared, with the shorter-duration group receiving fewer days of intravenous antibiotic therapy at baseline.⁶ In a 2024 before-and-after study, 3 versus 6 weeks of antibiotics were compared.⁷ The primary outcome in both studies was treatment failure within 6 months, with the results of each study showing similar failure rates between the shorter and longer duration therapy groups.^6,7 Secondary outcomes such as hospital readmission,⁶ antibiotic reinitiation,⁶ or need for a secondary amputation⁷ were also similar between groups.

Overall, retrospective analyses published after the 2023 IWGDF/IDSA guideline have continued to show that prolonged antibiotic duration is not associated with improved clinical outcomes following amputation for DFI in patients with residual bone infection.

Limitations
Several limitations should be considered when interpreting the available comparative evidence. Most notably, both studies were retrospective, included predominantly populations with DFI localized to the forefoot, and were potentially underpowered.^6,7 Neither study reported a formal sample size calculation, making it unclear whether the number of enrolled participants was sufficient to detect a clinically meaningful difference in treatment failure between antibiotic durations. This concern is particularly important for the 2022 study, which observed an approximately 12% absolute increase in failure rates in the shorter-duration group compared with the longer-duration group.⁶ In the 2024 study, 65% patients received antibiotic therapy prior to amputation for a median duration of 9 days, which increases the total duration of antimicrobial therapy and may attenuate differences between the postoperative treatment groups.⁷ Furthermore, despite a baseline imbalance favoring greater disease severity in the 6‑week group, as evidenced by higher rates of prior amputations, outcomes were similar across groups, suggesting no added benefit from extended therapy.

Conclusion
Current evidence suggests that shorter antibiotic durations of 3 to $\lt$4 weeks following DFI-related amputation with residual bone infection are comparable to longer courses of 4 to 6 weeks. Two comparative retrospective studies published after 2022 report similar rates of treatment failure when comparing 3 versus 6 weeks and $\lt$4 versus ≥4 weeks of therapy. These findings align with the 2023 IWGDF/IDSA guideline, which recommends up to 3 weeks of antibiotic therapy when residual bone infection remains after minor amputation, and are further supported by the 2025 WikiGuidelines Group, which advises that no more than 6 weeks of antibiotic therapy be administered for osteomyelitis when adequate source control has been achieved.

References

1. Beauduy CE, Cocohoba J, Fish DN. Skin and soft-tissue infections. In: Haines ST, Nolin TD, Ellingrod VL, Posey L, Cocohoba J, Holle L, eds. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach. 13th ed. McGraw Hill; 2026. Accessed February 19, 2026. https://accesspharmacy.mhmedical.com/content.aspx?bookid=3386§ionid=301509855
2. American Diabetes Association. Amputation Prevention Alliance. American Diabetes Association. Published 2024. Accessed February 26, 2026. https://diabetes.org/advocacy/amputation-prevention-alliance
3. Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023;ciad527. doi:10.1093/cid/ciad527
4. Gariani K, Pham TT, Kressmann B, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial. Clin Infect Dis. 2021;73(7):e1539-e1545. doi:10.1093/cid/ciaa1758.
5. Spellberg B, Ghanem B, Russell CD, et al. 2025 Update to WikiGuidelines for the management of pyogenic osteomyelitis in adults. Am J Med. Published online November 19, 2025. doi:10.1016/j.amjmed.2025.10.040
6. Motaganahalli S, Batrouney A, Perera D, Vogrin S, Trubiano JA. Retrospective study of outcomes of short versus long duration of antibiotic therapy for residual osteomyelitis in surgically resected diabetic foot infection. J Antimicrob Chemother. 2022;78(1):284-288. doi:10.1093/jac/dkac390
7. Petithomme-Nanrocki M, Slitine I, Diallo S, et al. Three versus six weeks of post-amputation antibiotic therapy in diabetic forefoot osteomyelitis with positive culture for residual infected bone. Infect Dis Now. 2024;54(7):104975. doi:10.1016/j.idnow.2024.104975

Prepared by:
Meerab Ayaz, PharmD Candidate 2026
UIC Retzky College of Pharmacy

Katherine Sarna, PharmD, BCPS
Clinical Assistant Professor, Drug Information Specialist
University of Illinois at Chicago College of Pharmacy

April 2026

The information presented is current as February 20, 2026. This information is intended as an educational piece and should not be used as the sole source for clinical decision-making.